Published in Urology on November 01, 2003
Three-piece Inflatable Penile Prosthesis: Surgical Techniques and Pitfalls. J Surg Tech Case Rep (2011) 1.10
Penile prosthesis implantation for the treatment for male erectile dysfunction: clinical outcomes and lessons learnt after 955 procedures. World J Urol (2012) 0.88
Modern utilization of penile prosthesis surgery: a national claim registry analysis. Int J Impot Res (2014) 0.82
Surgery: centers of excellence for penile prosthesis: yes or no? Nat Rev Urol (2009) 0.78
A practical overview of considerations for penile prosthesis placement. Nat Rev Urol (2015) 0.75
A review of surgical strategies for penile prosthesis implantation in patients with Peyronie's disease. Transl Androl Urol (2016) 0.75
Ischemic Gangrene of the Glans following Penile Prosthesis Implantation. Case Rep Urol (2013) 0.75
The impact of diabetes mellitus on penile length in men undergoing inflatable penile prosthesis implantation. Turk J Urol (2013) 0.75
Outcome of penile prosthesis implantation: are malleable prostheses an appropriate treatment option in patients with erectile dysfunction caused by prior radical surgery? Asian J Androl (2016) 0.75
The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med (2003) 11.25
Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy. J Clin Oncol (2007) 5.23
Update on AUA guideline on the management of benign prostatic hyperplasia. J Urol (2011) 5.01
Tolterodine and tamsulosin for treatment of men with lower urinary tract symptoms and overactive bladder: a randomized controlled trial. JAMA (2006) 4.15
Salvage radiotherapy for recurrent prostate cancer after radical prostatectomy. JAMA (2004) 4.10
A gain-of-function mutation in DHT synthesis in castration-resistant prostate cancer. Cell (2013) 2.94
Effect of 1 mg/day finasteride on concentrations of serum prostate-specific antigen in men with androgenic alopecia: a randomised controlled trial. Lancet Oncol (2007) 2.84
An updated catalog of prostate cancer predictive tools. Cancer (2008) 2.82
Cost comparison of robotic, laparoscopic, and open radical prostatectomy for prostate cancer. Eur Urol (2009) 2.76
A shifted paradigm for the further understanding, evaluation, and treatment of lower urinary tract symptoms in men: focus on the bladder. Eur Urol (2006) 2.74
The relationship between prostate inflammation and lower urinary tract symptoms: examination of baseline data from the REDUCE trial. Eur Urol (2007) 2.70
Use of combined apoptosis biomarkers for prediction of bladder cancer recurrence and mortality after radical cystectomy. Lancet Oncol (2007) 2.66
Urinary retention and post-void residual urine in men: separating truth from tradition. J Urol (2008) 2.57
Potential impact of adding genetic markers to clinical parameters in predicting prostate biopsy outcomes in men following an initial negative biopsy: findings from the REDUCE trial. Eur Urol (2012) 2.34
The value of your time: evaluation of effects of changes in medicare reimbursement rates on the practice of urology. J Urol (2004) 2.23
Predictive value of the differential expression of the urokinase plasminogen activation axis in radical prostatectomy patients. Eur Urol (2008) 2.20
Effects of tadalafil on lower urinary tract symptoms secondary to benign prostatic hyperplasia in men with or without erectile dysfunction. Urology (2010) 2.19
Association of the circulating levels of the urokinase system of plasminogen activation with the presence of prostate cancer and invasion, progression, and metastasis. J Clin Oncol (2007) 2.06
Alfuzosin 10 mg once daily in the management of acute urinary retention: results of a double-blind placebo-controlled study. Urology (2005) 2.01
Tadalafil for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia: pathophysiology and mechanism(s) of action. Neurourol Urodyn (2011) 1.93
Improved prediction of disease relapse after radical prostatectomy through a panel of preoperative blood-based biomarkers. Clin Cancer Res (2008) 1.90
Assessment of basic endoscopic performance using a virtual reality simulator. J Am Coll Surg (2002) 1.86
Sensitivity and specificity of commonly available bladder tumor markers versus cytology: results of a comprehensive literature review and meta-analyses. Urology (2003) 1.79
A refocus on the bladder as the originator of storage lower urinary tract symptoms: a systematic review of the latest literature. Eur Urol (2009) 1.76
Prostatic urethral lift: two-year results after treatment for lower urinary tract symptoms secondary to benign prostatic hyperplasia. Urology (2012) 1.71
Treatment of LUTS secondary to BPH while preserving sexual function: randomized controlled study of prostatic urethral lift. J Sex Med (2013) 1.71
Tadalafil relieves lower urinary tract symptoms secondary to benign prostatic hyperplasia. J Urol (2007) 1.70
Examination of the relationship between symptoms of prostatitis and histological inflammation: baseline data from the REDUCE chemoprevention trial. J Urol (2007) 1.69
The mechanism of growth-inhibitory effect of DOC-2/DAB2 in prostate cancer. Characterization of a novel GTPase-activating protein associated with N-terminal domain of DOC-2/DAB2. J Biol Chem (2002) 1.68
The interpretation of serum prostate specific antigen in men receiving 5alpha-reductase inhibitors: a review and clinical recommendations. J Urol (2006) 1.63
Lower urinary tract symptoms revisited: a broader clinical perspective. Eur Urol (2008) 1.62
PCPT: Evidence that finasteride reduces risk of most frequently detected intermediate- and high-grade (Gleason score 6 and 7) cancer. Urology (2009) 1.61
Management of ureteral calculi: a cost comparison and decision making analysis. J Urol (2002) 1.57
Alpha1-adrenoceptor subtypes and lower urinary tract symptoms. Int J Urol (2008) 1.55
Implications of the prostate cancer prevention trial: a decision analysis model of survival outcomes. J Clin Oncol (2005) 1.54
The effects of 5alpha-reductase inhibitors on the natural history, detection and grading of prostate cancer: current state of knowledge. J Urol (2005) 1.54
Prognostic value of syndecan-1 expression in patients treated with radical prostatectomy. BJU Int (2007) 1.50
Association of overactive bladder and C-reactive protein levels. Results from the Boston Area Community Health (BACH) Survey. BJU Int (2011) 1.50
Effect of increasing doses of saw palmetto extract on lower urinary tract symptoms: a randomized trial. JAMA (2011) 1.46
Prostate-specific antigen improves the ability of clinical stage and biopsy Gleason sum to predict the pathologic stage at radical prostatectomy in the new millennium. Eur Urol (2007) 1.45
Biopsy misidentification identified by DNA profiling in a large multicenter trial. J Clin Oncol (2011) 1.44
Baseline factors as predictors of clinical progression of benign prostatic hyperplasia in men treated with placebo. J Urol (2006) 1.42
Prediction of pathological stage is inaccurate in men with PSA values above 20 ng/mL. Eur Urol (2006) 1.42
Survivin expression is associated with features of biologically aggressive prostate carcinoma. Cancer (2004) 1.41
Soluble gp130 regulates prostate cancer invasion and progression in an interleukin-6 dependent and independent manner. J Urol (2011) 1.41
Comparison of the response to treatment between Asian and Caucasian men with benign prostatic hyperplasia: long-term results from the combination of dutasteride and tamsulosin study. Int J Urol (2012) 1.40
Are urologists fairly reimbursed for complex procedures: failure of 22 modifier? Urology (2008) 1.40
Herbal/hormonal dietary supplement possibly associated with prostate cancer progression. Clin Cancer Res (2008) 1.39
Prognosis of patients with pelvic lymph node (LN) metastasis after radical prostatectomy: value of extranodal extension and size of the largest LN metastasis. BJU Int (2014) 1.39
The effect of combined androgen ablation on the expression of alpha1A-adrenergic receptor in the human prostate. Prostate (2004) 1.38
Methods of developing UWIN, the modified American Urological Association symptom score. J Urol (2011) 1.37
Study design of the Medical Therapy of Prostatic Symptoms (MTOPS) trial. Control Clin Trials (2003) 1.33
A multi-institutional matched-control analysis of adjuvant and salvage postoperative radiation therapy for pT3-4N0 prostate cancer. Urology (2008) 1.32
Add-on fesoterodine for residual storage symptoms suggestive of overactive bladder in men receiving α-blocker treatment for lower urinary tract symptoms. BJU Int (2011) 1.31
Reduction in hospital admission rates due to post-prostate biopsy infections after augmenting standard antibiotic prophylaxis. J Urol (2012) 1.30
Caveolin-1 overexpression is associated with aggressive prostate cancer recurrence. Prostate (2007) 1.29
Idiopathic scrotal elephantiasis. Urology (2005) 1.28
Critical analysis of the relationship between sexual dysfunctions and lower urinary tract symptoms due to benign prostatic hyperplasia. Eur Urol (2011) 1.26
Critical review of lasers in benign prostatic hyperplasia (BPH). BJU Int (2011) 1.25
Benign prostatic hyperplasia evaluation and management by urologists and primary care physicians: practice patterns from the observational BPH registry. J Urol (2011) 1.25
Cost-effectiveness of prostate cancer chemoprevention: a quality of life-years analysis. Cancer (2008) 1.21
External validation of a biomarker-based preoperative nomogram predicts biochemical recurrence after radical prostatectomy. J Clin Oncol (2008) 1.18
Variation in institutional review board responses to a standard protocol for a multicenter randomized, controlled surgical trial. J Urol (2009) 1.18
Salvage radiotherapy for biochemical failure of radical prostatectomy: a single-institution experience. Urology (2003) 1.18
Anthropometric and metabolic factors and risk of benign prostatic hyperplasia: a prospective cohort study of Air Force veterans. Urology (2006) 1.14
Comparison of stage migration patterns between Europe and the USA: an analysis of 11 350 men treated with radical prostatectomy for prostate cancer. BJU Int (2008) 1.11
Evidence-based validation of the predictive value of the American Association for the Surgery of Trauma kidney injury scale. J Trauma (2007) 1.11
The Clinical Benefits of Dutasteride Treatment for LUTS and BPH. Rev Urol (2004) 1.11
Do oral antimuscarinic drugs carry an increased risk of acute urinary retention? J Urol (2009) 1.10
The effect of the approach to radical prostatectomy on the profitability of hospitals and surgeons. BJU Int (2009) 1.10
Sustained decrease in incidence of acute urinary retention and surgery with finasteride for 6 years in men with benign prostatic hyperplasia. J Urol (2004) 1.09
Relationship between prostate specific antigen and indexes of prostate volume in Japanese men. J Urol (2005) 1.09
Do urological symptoms cluster among women? Results from the Boston Area Community Health Survey. BJU Int (2008) 1.09
Combination therapy with dutasteride and tamsulosin in men with moderate-to-severe benign prostatic hyperplasia and prostate enlargement: the CombAT (Combination of Avodart and Tamsulosin) trial rationale and study design. Contemp Clin Trials (2007) 1.07
Variability in the performance of nuclear matrix protein 22 for the detection of bladder cancer. J Urol (2006) 1.06
Implications of recent epidemiology studies for the clinical management of lower urinary tract symptoms. BJU Int (2009) 1.06
Development of nomogram to predict acute urinary retention or surgical intervention, with or without dutasteride therapy, in men with benign prostatic hyperplasia. Urology (2006) 1.04
Pre-treatment biomarker levels improve the accuracy of post-prostatectomy nomogram for prediction of biochemical recurrence. Prostate (2009) 1.02
Using biopsy to detect prostate cancer. Rev Urol (2008) 1.00
The cost of prostate cancer chemoprevention: a decision analysis model. Cancer Epidemiol Biomarkers Prev (2006) 1.00
Virtual ureteroscopy predicts ureteroscopic proficiency of medical students on a cadaver. J Urol (2004) 1.00
Correlation of the International Prostate Symptom Score bother question with the Benign Prostatic Hyperplasia Impact Index in a clinical practice setting. BJU Int (2008) 0.99
Expression of survivin and apoptotic biomarkers in benign prostatic hyperplasia. J Urol (2005) 0.99
Predictive value of primary Gleason pattern 4 in patients with Gleason score 7 tumours treated with radical prostatectomy. BJU Int (2004) 0.99